Literature DB >> 23801403

Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI.

Giovanni Foti1, Letizia Boninsegna, Massimo Falconi, Roberto Pozzi Mucelli.   

Abstract

PURPOSE: This study was done to compare the diagnostic accuracy of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) in the preoperative assessment of nonfunctioning pancreatic endocrine tumours (NFPET).
MATERIALS AND METHODS: Fifty-one patients (25 men, 26 women; mean age, 52 years), preoperatively investigated by both MDCT and MRI and subsequently operated on with a histological diagnosis of NFPET, were included in this study. MDCT and MRI accuracy in evaluating location, size, margins, baseline density/signal intensity, structure, pattern of enhancement, peak enhancement phase, involvement of main pancreatic duct, involvement of adjacent organs, infiltration of peritumoural vessels, involvement of locoregional lymph nodes, and liver metastases was compared using Pearson correlation, Mann-Whitney and chi-square tests. A value of p<0.05 was considered statistically significant.
RESULTS: MDCT and MRI had similar accuracy in assessing size, margins, baseline density/signal intensity, structure, pattern of enhancement, peak enhancement phase, involvement of main pancreatic duct, involvement of adjacent organs, involvement of locoregional lymph nodes, and liver metastases (p>0.05). MDCT was superior to MRI in evaluating the infiltration of peritumoural vessels (p=0.025).
CONCLUSIONS: MDCT performed better than MRI in assessing vascular involvement and should be considered the best imaging tool for preoperative evaluation of NFPET.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801403     DOI: 10.1007/s11547-013-0956-5

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  34 in total

1.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 2.  Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors.

Authors:  M Bäder; K Koppenhagen
Journal:  Recent Results Cancer Res       Date:  1996

3.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Authors:  Francesco Panzuto; Letizia Boninsegna; Nicola Fazio; Davide Campana; Maria Pia Brizzi; Gabriele Capurso; Aldo Scarpa; Filippo De Braud; Luigi Dogliotti; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 4.  Imaging of neuroendocrine gastroenteropancreatic tumours.

Authors:  R Graziani; A Brandalise; M Bellotti; R Manfredi; A Contro; M Falconi; L Boninsegna; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2010-03-09       Impact factor: 3.469

5.  Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics.

Authors:  Yi Wang; Zongming E Chen; Vahid Yaghmai; Paul Nikolaidis; Robert J McCarthy; Laura Merrick; Frank H Miller
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

Review 6.  Nuclear medicine imaging of neuroendocrine tumours.

Authors:  E Bombardieri; M Maccauro; E De Deckere; G Savelli; A Chiti
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

7.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

Review 8.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

Review 9.  Surgical management of pancreatic endocrine tumors.

Authors:  Volker Fendrich; Jens Waldmann; Detlef K Bartsch; Peter Langer
Journal:  Nat Rev Clin Oncol       Date:  2009-06-09       Impact factor: 66.675

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  5 in total

1.  Enhancing pancreatic mass with normal serum CA19-9: key MDCT features to characterize pancreatic neuroendocrine tumours from its mimics.

Authors:  Liang Zhu; Hua-Dan Xue; Wei Liu; Xuan Wang; Xin Sui; Qin Wang; Daming Zhang; Ping Li; Zheng-Yu Jin
Journal:  Radiol Med       Date:  2017-02-15       Impact factor: 3.469

2.  Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Authors:  Yanji Luo; Zhi Dong; Jie Chen; Tao Chan; Yuan Lin; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2014-07-22       Impact factor: 5.315

Review 3.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

4.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

5.  Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.

Authors:  C G Genç; M Falconi; S Partelli; F Muffatti; S van Eeden; C Doglioni; H J Klümpen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  Ann Surg Oncol       Date:  2018-05-22       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.